Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 13 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Glaxosmithkline Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 12, 2025, 1:41 pm

Market Cap 46,382 Cr.
Current Price 2,737
High / Low 3,088/1,825
Stock P/E54.3
Book Value 98.7
Dividend Yield1.20 %
ROCE51.3 %
ROE37.3 %
Face Value 10.0
PEG Ratio2.84

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Glaxosmithkline Pharmaceuticals Ltd

Competitors of Glaxosmithkline Pharmaceuticals Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 156 Cr. 111 247/10322.5 36.50.00 %18.0 %15.5 % 10.0
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.0 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 39.3 Cr. 26.8 29.0/8.7440.1 6.640.00 %2.65 %2.08 % 10.0
Industry Average16,991.03 Cr1,044.9041.11182.720.37%16.01%16.31%6.24

All Competitor Stocks of Glaxosmithkline Pharmaceuticals Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 8168107459178027877629578059308151,011949
Expenses 618634596660574618618668587673584689658
Operating Profit 198175149257229170144289218257231322292
OPM % 24%22%20%28%29%22%19%30%27%28%28%32%31%
Other Income 41,322312212385428-13532363935
Interest 1010010001000
Depreciation 18151616161716181718161719
Profit before tax 1841,48216326222419018129965271249344308
Tax % 18%18%27%26%27%30%27%27%30%28%27%27%25%
Net Profit 1501,21911919316513313221846194182252230
EPS in Rs 8.8871.967.0411.429.717.887.8112.842.7011.4810.7614.9113.57

Last Updated: February 28, 2025, 7:50 pm

Below is a detailed analysis of the quarterly data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹949.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,011.00 Cr. (Sep 2024) to ₹949.00 Cr., marking a decrease of 62.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹658.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 689.00 Cr. (Sep 2024) to ₹658.00 Cr., marking a decrease of 31.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹292.00 Cr.. The value appears to be declining and may need further review. It has decreased from 322.00 Cr. (Sep 2024) to ₹292.00 Cr., marking a decrease of 30.00 Cr..
  • For OPM %, as of Dec 2024, the value is 31.00%. The value appears to be declining and may need further review. It has decreased from 32.00% (Sep 2024) to 31.00%, marking a decrease of 1.00%.
  • For Other Income, as of Dec 2024, the value is ₹35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Sep 2024) to ₹35.00 Cr., marking a decrease of 4.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Sep 2024) to ₹19.00 Cr., marking an increase of ₹2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹308.00 Cr.. The value appears to be declining and may need further review. It has decreased from 344.00 Cr. (Sep 2024) to ₹308.00 Cr., marking a decrease of 36.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Sep 2024) to 25.00%, marking a decrease of 2.00%.
  • For Net Profit, as of Dec 2024, the value is ₹230.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Sep 2024) to ₹230.00 Cr., marking a decrease of 22.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 13.57. The value appears to be declining and may need further review. It has decreased from ₹14.91 (Sep 2024) to 13.57, marking a decrease of ₹1.34.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:13 pm

MetricDec 2012Dec 2013Mar 2015n n 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 2,6472,5633,3052,8382,9082,8713,1283,2242,9263,2783,2523,4543,705
Expenses 1,8242,0342,6722,3602,4892,3632,5272,5672,3272,5162,4472,5452,603
Operating Profit 8225286334784205086016575987628049091,101
OPM % 31%21%19%17%14%18%19%20%20%23%25%26%30%
Other Income 3020314912511970131-26291,401103-21142
Interest 0000001642222
Depreciation 18202525273849837968667070
Profit before tax 8347117565785115406833065252,0938398161,172
Tax % 33%32%37%35%34%35%35%70%32%19%27%28%
Net Profit 562482476376337351445933581,695611590859
EPS in Rs 33.1728.4328.1222.2019.8820.7026.295.5021.14100.0436.0534.8350.72
Dividend Payout % 75%88%111%113%75%85%76%727%142%90%89%92%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-10.37%4.15%26.78%-79.10%284.95%373.46%-63.95%-3.44%
Change in YoY Net Profit Growth (%)0.00%14.53%22.63%-105.88%364.05%88.52%-437.42%60.52%

Glaxosmithkline Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:3%
5 Years:2%
3 Years:6%
TTM:12%
Compounded Profit Growth
10 Years:4%
5 Years:9%
3 Years:11%
TTM:33%
Stock Price CAGR
10 Years:5%
5 Years:16%
3 Years:20%
1 Year:39%
Return on Equity
10 Years:28%
5 Years:37%
3 Years:49%
Last Year:37%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 11:41 pm

MonthDec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 858585858585169169169169169169169
Reserves 1,9221,9051,7442,0991,9221,9731,9701,6511,3092,4941,5721,6081,503
Borrowings 543221103520161915
Other Liabilities 1,0771,1361,3848699951,8891,7711,3121,6021,9501,5701,7602,059
Total Liabilities 3,0883,1303,2163,0553,0043,9473,9113,1333,1154,6333,3273,5573,746
Fixed Assets 89100123204258325432758387331330321296
CWIP 44621152686059231,0031201330201421
Investments 551006000003665188131,001
Other Assets 2,9002,9582,9772,5772,1402,7002,4772,2552,7153,9072,4582,4082,428
Total Assets 3,0883,1303,2163,0553,0043,9473,9113,1333,1154,6333,3273,5573,746

Below is a detailed analysis of the balance sheet data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹169.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹1,503.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,608.00 Cr. (Mar 2024) to ₹1,503.00 Cr., marking a decrease of 105.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹15.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹19.00 Cr. (Mar 2024) to ₹15.00 Cr., marking a decrease of 4.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹2,059.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,760.00 Cr. (Mar 2024) to ₹2,059.00 Cr., marking an increase of 299.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹3,746.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹3,557.00 Cr. (Mar 2024) to ₹3,746.00 Cr., marking an increase of 189.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹296.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹321.00 Cr. (Mar 2024) to ₹296.00 Cr., marking a decrease of 25.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹21.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹14.00 Cr. (Mar 2024) to ₹21.00 Cr., marking an increase of 7.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹1,001.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹813.00 Cr. (Mar 2024) to ₹1,001.00 Cr., marking an increase of 188.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹2,428.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,408.00 Cr. (Mar 2024) to ₹2,428.00 Cr., marking an increase of 20.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹3,746.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹3,557.00 Cr. (Mar 2024) to ₹3,746.00 Cr., marking an increase of 189.00 Cr..

Notably, the Reserves (₹1,503.00 Cr.) exceed the Borrowings (15.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthDec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +314281338139234473409490578811484582
Cash from Investing Activity +-110189180499301-104-153-57418-4068089
Cash from Financing Activity +-441-494-497-638-511-307-358-428-696-524-1,543-562
Net Cash Flow-237-2421-02462-1026300-119-25129

Free Cash Flow

MonthDec 2012Dec 2013Mar 2015n n 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow817.00524.00633.00476.00418.00507.00600.00657.00563.00742.00788.00890.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days161411162119141127232223
Inventory Days9410991156111147131135159144131144
Days Payable7890749773149109100135156122171
Cash Conversion Cycle3233277560173646501131-4
Working Capital Days-42-45-48267-90-72-38-37-92-55-62
ROCE %50%34%42%29%22%26%31%33%38%37%36%51%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs2.18%2.16%2.17%2.28%2.28%2.41%2.50%2.93%3.48%4.02%4.36%4.50%
DIIs10.73%10.65%10.54%10.29%10.31%10.25%10.01%8.64%7.90%7.51%7.34%7.30%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.00%0.00%0.00%0.00%
Public12.09%12.19%12.29%12.43%12.43%12.35%12.48%13.42%13.62%13.48%13.30%13.21%
No. of Shareholders1,10,1411,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,6631,18,9941,18,5151,19,2281,19,625

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life ELSS Tax Saver Fund1,218,8721.42201.98753,2572025-03-1161.81%
Nippon India Pharma Fund853,9072.28141.5753,2572025-03-1113.36%
ICICI Prudential Large & Mid Cap Fund839,1791.44139.06753,2572025-03-1111.41%
SBI Magnum Midcap Fund806,8950.93133.71753,2572025-03-117.12%
Aditya Birla Sun Life MNC Fund - Div753,6003.58124.88753,2572025-03-110.05%
Aditya Birla Sun Life MNC Fund - Gr753,6003.58124.88753,2572025-03-110.05%
ICICI Prudential Multi Asset Fund753,2570.45124.82753,2572025-03-110%
Nippon India Growth Fund559,0000.4392.63753,2572025-03-11-25.79%
ICICI Prudential Value Discovery Fund355,1840.1758.86753,2572025-03-11-52.85%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund293,8141.4848.69753,2572025-03-11-60.99%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 41.1436.0899.2931.355.50
Diluted EPS (Rs.) 34.8336.05100.0421.145.50
Cash EPS (Rs.) 38.9439.93104.0625.7810.38
Book Value[Excl.RevalReserv]/Share (Rs.) 104.93102.79157.1987.26107.47
Book Value[Incl.RevalReserv]/Share (Rs.) 104.93102.79157.1987.26107.47
Revenue From Operations / Share (Rs.) 203.87191.95193.50172.70190.33
PBDIT / Share (Rs.) 60.8853.4249.4541.8443.46
PBIT / Share (Rs.) 56.7649.5445.4237.2038.58
PBT / Share (Rs.) 48.1849.3745.9926.8018.05
Net Profit / Share (Rs.) 34.8336.05100.0421.145.50
NP After MI And SOA / Share (Rs.) 35.0736.41100.0421.145.50
PBDIT Margin (%) 29.8627.8225.5524.2222.83
PBIT Margin (%) 27.8425.8023.4721.5320.26
PBT Margin (%) 23.6325.7223.7615.519.48
Net Profit Margin (%) 17.0818.7851.6912.242.89
NP After MI And SOA Margin (%) 17.2018.9651.6912.242.89
Return on Networth / Equity (%) 33.4235.4163.6424.225.11
Return on Capital Employeed (%) 47.3341.9526.2135.8030.95
Return On Assets (%) 16.7018.5336.5711.492.97
Asset Turnover Ratio (%) 1.000.800.830.930.91
Current Ratio (X) 1.841.882.181.631.74
Quick Ratio (X) 1.491.531.871.221.26
Inventory Turnover Ratio (X) 1.110.811.040.890.97
Dividend Payout Ratio (NP) (%) 91.24247.2129.98189.20363.51
Dividend Payout Ratio (CP) (%) 81.66223.3928.82155.15192.63
Earning Retention Ratio (%) 8.76-147.2170.02-89.20-263.51
Cash Earning Retention Ratio (%) 18.34-123.3971.18-55.15-92.63
Interest Coverage Ratio (X) 573.35499.36419.65200.69116.21
Interest Coverage Ratio (Post Tax) (X) 408.84336.84185.96131.2269.61
Enterprise Value (Cr.) 31854.0621275.9725686.8623243.3020012.10
EV / Net Operating Revenue (X) 9.226.547.847.946.21
EV / EBITDA (X) 30.8923.5130.6732.8027.18
MarketCap / Net Operating Revenue (X) 9.536.908.598.346.54
Retention Ratios (%) 8.75-147.2170.01-89.20-263.51
Price / BV (X) 18.5212.8810.5816.5111.59
Price / Net Operating Revenue (X) 9.536.908.598.346.54
EarningsYield 0.010.020.060.010.00

After reviewing the key financial ratios for Glaxosmithkline Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 41.14. This value is within the healthy range. It has increased from 36.08 (Mar 23) to 41.14, marking an increase of 5.06.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 34.83. This value is within the healthy range. It has decreased from 36.05 (Mar 23) to 34.83, marking a decrease of 1.22.
  • For Cash EPS (Rs.), as of Mar 24, the value is 38.94. This value is within the healthy range. It has decreased from 39.93 (Mar 23) to 38.94, marking a decrease of 0.99.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 104.93. It has increased from 102.79 (Mar 23) to 104.93, marking an increase of 2.14.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 104.93. It has increased from 102.79 (Mar 23) to 104.93, marking an increase of 2.14.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 203.87. It has increased from 191.95 (Mar 23) to 203.87, marking an increase of 11.92.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 60.88. This value is within the healthy range. It has increased from 53.42 (Mar 23) to 60.88, marking an increase of 7.46.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 56.76. This value is within the healthy range. It has increased from 49.54 (Mar 23) to 56.76, marking an increase of 7.22.
  • For PBT / Share (Rs.), as of Mar 24, the value is 48.18. This value is within the healthy range. It has decreased from 49.37 (Mar 23) to 48.18, marking a decrease of 1.19.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 34.83. This value is within the healthy range. It has decreased from 36.05 (Mar 23) to 34.83, marking a decrease of 1.22.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 35.07. This value is within the healthy range. It has decreased from 36.41 (Mar 23) to 35.07, marking a decrease of 1.34.
  • For PBDIT Margin (%), as of Mar 24, the value is 29.86. This value is within the healthy range. It has increased from 27.82 (Mar 23) to 29.86, marking an increase of 2.04.
  • For PBIT Margin (%), as of Mar 24, the value is 27.84. This value exceeds the healthy maximum of 20. It has increased from 25.80 (Mar 23) to 27.84, marking an increase of 2.04.
  • For PBT Margin (%), as of Mar 24, the value is 23.63. This value is within the healthy range. It has decreased from 25.72 (Mar 23) to 23.63, marking a decrease of 2.09.
  • For Net Profit Margin (%), as of Mar 24, the value is 17.08. This value exceeds the healthy maximum of 10. It has decreased from 18.78 (Mar 23) to 17.08, marking a decrease of 1.70.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 17.20. This value is within the healthy range. It has decreased from 18.96 (Mar 23) to 17.20, marking a decrease of 1.76.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 33.42. This value is within the healthy range. It has decreased from 35.41 (Mar 23) to 33.42, marking a decrease of 1.99.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 47.33. This value is within the healthy range. It has increased from 41.95 (Mar 23) to 47.33, marking an increase of 5.38.
  • For Return On Assets (%), as of Mar 24, the value is 16.70. This value is within the healthy range. It has decreased from 18.53 (Mar 23) to 16.70, marking a decrease of 1.83.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 1.00. It has increased from 0.80 (Mar 23) to 1.00, marking an increase of 0.20.
  • For Current Ratio (X), as of Mar 24, the value is 1.84. This value is within the healthy range. It has decreased from 1.88 (Mar 23) to 1.84, marking a decrease of 0.04.
  • For Quick Ratio (X), as of Mar 24, the value is 1.49. This value is within the healthy range. It has decreased from 1.53 (Mar 23) to 1.49, marking a decrease of 0.04.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.11. This value is below the healthy minimum of 4. It has increased from 0.81 (Mar 23) to 1.11, marking an increase of 0.30.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 91.24. This value exceeds the healthy maximum of 50. It has decreased from 247.21 (Mar 23) to 91.24, marking a decrease of 155.97.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 81.66. This value exceeds the healthy maximum of 50. It has decreased from 223.39 (Mar 23) to 81.66, marking a decrease of 141.73.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 8.76. This value is below the healthy minimum of 40. It has increased from -147.21 (Mar 23) to 8.76, marking an increase of 155.97.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 18.34. This value is below the healthy minimum of 40. It has increased from -123.39 (Mar 23) to 18.34, marking an increase of 141.73.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 573.35. This value is within the healthy range. It has increased from 499.36 (Mar 23) to 573.35, marking an increase of 73.99.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 408.84. This value is within the healthy range. It has increased from 336.84 (Mar 23) to 408.84, marking an increase of 72.00.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 31,854.06. It has increased from 21,275.97 (Mar 23) to 31,854.06, marking an increase of 10,578.09.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 9.22. This value exceeds the healthy maximum of 3. It has increased from 6.54 (Mar 23) to 9.22, marking an increase of 2.68.
  • For EV / EBITDA (X), as of Mar 24, the value is 30.89. This value exceeds the healthy maximum of 15. It has increased from 23.51 (Mar 23) to 30.89, marking an increase of 7.38.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 9.53. This value exceeds the healthy maximum of 3. It has increased from 6.90 (Mar 23) to 9.53, marking an increase of 2.63.
  • For Retention Ratios (%), as of Mar 24, the value is 8.75. This value is below the healthy minimum of 30. It has increased from -147.21 (Mar 23) to 8.75, marking an increase of 155.96.
  • For Price / BV (X), as of Mar 24, the value is 18.52. This value exceeds the healthy maximum of 3. It has increased from 12.88 (Mar 23) to 18.52, marking an increase of 5.64.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 9.53. This value exceeds the healthy maximum of 3. It has increased from 6.90 (Mar 23) to 9.53, marking an increase of 2.63.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Glaxosmithkline Pharmaceuticals Ltd as of March 13, 2025 is: ₹1,618.44

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 13, 2025, Glaxosmithkline Pharmaceuticals Ltd is Overvalued by 40.87% compared to the current share price 2,737.00

Intrinsic Value of Glaxosmithkline Pharmaceuticals Ltd as of March 13, 2025 is: 1,928.02

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 13, 2025, Glaxosmithkline Pharmaceuticals Ltd is Overvalued by 29.56% compared to the current share price 2,737.00

Last 5 Year EPS CAGR: 19.13%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 35.75%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -45.67, which is a positive sign.
  3. The company has higher reserves (1,820.92 cr) compared to borrowings (9.46 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (2.54 cr) and profit (546.31 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 34.50, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glaxosmithkline Pharmaceuticals Ltd:
    1. Net Profit Margin: 17.08%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 47.33% (Industry Average ROCE: 15.88%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 33.42% (Industry Average ROE: 15.78%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 408.84
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.49
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 54.3 (Industry average Stock P/E: 33.02)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 3407.25 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsGSK House, Dr. Annie Besant Road, Mumbai Maharashtra 400030in.investorquery@gsk.com
http://www.gsk-india.com
Management
NamePosition Held
Ms. R S KarnadChairperson
Mr. B AkshikarManaging Director
Mr. J ChandyWholeTime Director & CFO
Mr. S WilliamsNon Executive Director
Mr. M AnandIndependent Director
Dr.(Ms.) S MaheshwariIndependent Director
Mr. A N RoyIndependent Director
Mr. D SundaramIndependent Director
Mr. P V BhideIndependent Director

FAQ

What is the latest intrinsic value of Glaxosmithkline Pharmaceuticals Ltd?

The latest intrinsic value of Glaxosmithkline Pharmaceuticals Ltd as on 13 March 2025 is ₹1618.44, which is 40.87% lower than the current market price of ₹2,737.00, indicating the stock is overvalued by 40.87%. The intrinsic value of Glaxosmithkline Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹46,382 Cr. and recorded a high/low of ₹3,088/1,825 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,503 Cr and total liabilities of ₹3,746 Cr.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

The Market Cap of Glaxosmithkline Pharmaceuticals Ltd is 46,382 Cr..

What is the current Stock Price of Glaxosmithkline Pharmaceuticals Ltd as on 13 March 2025?

The current stock price of Glaxosmithkline Pharmaceuticals Ltd as on 13 March 2025 is ₹2,737.

What is the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks is ₹3,088/1,825.

What is the Stock P/E of Glaxosmithkline Pharmaceuticals Ltd?

The Stock P/E of Glaxosmithkline Pharmaceuticals Ltd is 54.3.

What is the Book Value of Glaxosmithkline Pharmaceuticals Ltd?

The Book Value of Glaxosmithkline Pharmaceuticals Ltd is 98.7.

What is the Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd?

The Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd is 1.20 %.

What is the ROCE of Glaxosmithkline Pharmaceuticals Ltd?

The ROCE of Glaxosmithkline Pharmaceuticals Ltd is 51.3 %.

What is the ROE of Glaxosmithkline Pharmaceuticals Ltd?

The ROE of Glaxosmithkline Pharmaceuticals Ltd is 37.3 %.

What is the Face Value of Glaxosmithkline Pharmaceuticals Ltd?

The Face Value of Glaxosmithkline Pharmaceuticals Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Glaxosmithkline Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE